Smallpox vaccine helps Bavarian Nordic net first full-year profit in 5 years

An article from FierceVaccines
March 12, 2015
After a four-year drought, Bavarian Nordic has finally had its first full year of profit, and it has its smallpox vaccine to thank.
 
The company announced Wednesday that it had a full-year net profit of 25.9 Danish kroner ($3.72 million) and that it expects 1.1 billion kroner ($159 million) in revenue for 2015. The Danish biotech said in its annual report that it made most of its fiscal 2014 revenue from sales of Imvamune, its smallpox vaccine, to the U.S. Strategic National Stockpile.
 
Just this month, Bavarian Nordic inked a deal with Bristol-Myers Squibb ($BMY) on its prostate cancer vaccine, Prostvac. The candidate is currently in Phase III and Bristol-Myers will hand over $60 million up front, with more than $915 million to follow in milestones if it licenses and commercializes the vaccine.
 
Read more here
Common Disease Taxonomy: 
Common Vaccine Taxonomy: 
Common Management Taxonomy: 
0